Oral Mucositis Treatment Landscape in 7MM Examined by DelveInsight in Its Topical Research Report Available at MarketPublishers.com
26 Sep 2017 • by Natalie Aster
LONDON – Oral mucositis is deemed to be one of the most typical problems associated with cancer chemotherapy. These painful mouth sores occur in 20%-40% of adult cancer carriers getting traditional chemical therapy for solid tumours, nearly 80% of patients receiving high doses of chemo before hematopoietic stem cell (HSC) transplantation, and almost all patients receiving radiation therapy for cancers of the head and neck.
Additionally, the oral mucositis occurs in 70% of the patients with cancers of the mouth, oral pharynx, laryngeal pharynx, larynx, nasal pharynx, and salivary glands. Close to 500,000 oral mucositis cases take place in the USA. The incidence rate of the complication varies across cancer patient populations and has relation to individual patient factors and the therapy type being received.
Topical market research study “Oral Mucositis - Epidemiology Insights to 2025” drawn up by DelveInsight is dedicated to thoroughly examining the market for oral mucositis therapy landscape.
The report gives a detailed disease overview, including pathophysiology, diagnosis, disease control, symptoms, and today’s treatment modalities. It provides global epidemiological data (historical and projected) for oral mucositis for the 7 leading markets (7MM), namely the USA, EU5 (France, Germany, Italy, Spain, the UK) and Japan from 2015 through to 2025. The research publication offers in-depth insights into the overall incidence, gender specific, grade specific, and indication specific incidence rates of oral mucositis across the 7MM.
More topical market research reports by this publisher are at hand at DelveInsight page.